Up to two research calls per year
Research grants
Currently, the majority of our funding is awarded via research grants to academic institutions, although consortia including industry are welcome to apply.
Usually, two scheduled calls for research proposals are held each year. They can either be ‘All priorities’ calls which means that project topics should fit within one or more of EB-ResNet’s four strategic research priorities. Alternatively, a scheduled ‘Special’ call may be issued to invite proposals to address identified important unmet research questions, technology needs or clinical consequences arising from EB (e.g. chronic inflammation and fibrosis).
Project scope 'Research grants'
- Fundamental to preclinical research, and clinical trials projects in EB
- Research projects must fall into the scope of a current research call: either an 'All priorities' call or a 'Special call' i.e. chronic inflammation and fibrosis
- Lead applicant: researchers and/or clinicians (cooperation with industry welcome and possible)
- Project duration: 12 to 36 months
- Funding: up to EUR 90,000.00 p.a.
Current & upcoming Calls
The last call for research proposals closed on 6. April 2020. Details on scope and submission deadlines are found under last call.
Due to the current Covid-19 crisis it is not clear when the next research call will be launched. Information will be published in due time.
Funded projects (EB-ResNet & DEBRA International research calls)
Grant Round/ Call
| Project lead | Organisation/ Institute | Duration | Research area | EB-type | Funder(s) |
| CIF Call 2018 | Prof. Giovanna Zambruno | Bambino Gesu Ospedale, Italy | 3 years | Clinical research RNA-therapy Fibrosis | Dystrophic
| DEBRA Austria DEBRA UK DEBRA Spain |
| CIF Call 2018 | Prof. Ulrich Rodeck taken over by Prof. Andy South | Thomas Jefferson University, USA | 2 years | Clinical research Small molecules Fibrosis | Dystrophic | DEBRA Austria DEBRA Ireland |
| CIF Call 2018 | Dr. Yanling Liao | New York Medical College, USA | 3 years | Clinical research Cancer | Dystrophic | DEBRA UK DEBRA Ireland |
| All Priorities 2019 | Prof. Valerie Brunton | University of Edinburgh, UK | 3 years | Fundamental research Cancer | Kindler | DEBRA Austria DEBRA UK |
| All Priorities 2019 | Prof. Karine Raymond | Leiden University Medical Center, The Netherlands | 3 years | Fundamental research Pluripotent stem cells | Simplex | DEBRA Austria |
| All Priorities 2019 | Dr. Colin Butler | University College London, Great Ormond Street Institute of Child Health, UK | 2 years | Fundamental research Cellular and molecular therapy | Junctional | DEBRA Austria DEBRA UK |
| All Priorities 2019 | Prof. Liam Grover | University of Birmingham, UK | 2 years | Preclinical research Small molecules | Dystrophic | DEBRA UK DEBRA Ireland |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
Innovative Research Grant Call 2017 | Dr. Cédric Gaggioli | Association pour le Développement des Sciences Médicales, Faculté de Médicine, France | 1 year | Fundamental research Small molecules | Dystrophic | DEBRA Austria |
All Priorities Call 2018 | Prof. Jouni Uitto | Thomas Jefferson University, Philadelphia USA | 2 years | Fundamental research Molecular diagnostics | Dystrophic Junctional Simplex | DEBRA Austria |
All Priorities Call 2018 | Prof. Ganna Bilousova | University of Colorado, USA | 3 years | Fundamental research Cellular and molecular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2018 | Dr. Su Lwin | Kings College London, UK | 2 years | Gene therapy SSC | Dystrophic | DEBRA UK |
All Priorities Call 2018 | Prof. Gareth Inman | University of Glasgow | 1 year | SSC | Dystrophic | DEBRA UK |
All Priorities Call 2018 | Prof. Iain Chapple | University of Birmingham | 3 years | EB biology | All types | DEBRA UK |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2017 | Prof. Cristina Has | University of Freiburg, Germany | 1 year | Fundamental research Genetics | Simplex | DEBRA Austria |
All Priorities Call 2017 | Dr. Antonia Reimer | University of Freiburg, Germany | 3 years | Fundamental research Clinical characterization | Dystrophic Junctional | DEBRA Austria |
Innovative Research Grant Call 2017 | Prof. Margarita Calvo | Pontificia Universidad Católica de Chile, Chile | 1,5 years | Fundamental research Small molecules Symptom relief | Dystrophic | DEBRA Austria
|
All Priorities Call 2017 | Prof. Daniele Castiglia | IRCCS, Rome, Italy | 3 years | Fundamental research Small molecules Woundhealing | Dystrophic | DEBRA Austria DEBRA UK |
All Priorities Call 2017 | Prof. Thomas Magin | University of Leipzig, Germany | 3 years | Fundamental research Small molecules | Simplex | DEBRA Austria |
All Priorities Call 2017 | Prof. Alain Hovnanian | INSERM, Departement of Genetics, France | 2 years | Fundamental research Cellular and molecular therapy | Dystrophic | DEBRA Austria |
| CliniCall 2015 | Prof. Peter Marinkovich terminated | Stanford University, USA | 3 years | Clinical trial Phase II Cellular and molecular therapy | Dystrophic | DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2016 | Dr. Fernando Larcher | CIEMAT - Centro de Investigaciones Energéticas Medioambientales y Tecnológicas Prospósito, SPAIN | 2 years | Molecular therapy, Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2016 | Prof. Arnoud Sonnenberg | Netherlands Cancer Institute, THE NETHERLANDS | 2 years | Molecular therapy, Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2016 | Prof. Jouni Uitto | Thomas Jefferson University, Philadelphia, USA | 2 years | EB genetics, epigenetics & biology | Simplex Dystrophic Junctional |
DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2015 | Dr. Andrew South | Thomas Jefferson University, Philardelphia, USA | 2 years | Molecular therapy, cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2015 | Dr. Marius Wernig | Standord University, California, USA | 3 years | Molecular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2015 | Prof. Leena Bruckner- Tuderman | University of Freiburg Medical Center, Departement of Determatology, GERMANY | 4 years | Clinical trial Phase II | Dystrophic | DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2014 | Prof. Mitchell Cairo | New York Medical College, New York, USA | 2 years (+ 1) | Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2014 | Prof. Crstina Has | University of Freiburg Medical Center, Departement of Dermatology, GERMANY | 2 years | EB genetics, epigenetics & biology | Simplex | DEBRA Austria |
All Priorities Call 2014 | Dr. Mark Saville | Ninewells Hospital and Medical School, University of Dundee, UK | 3 years | Skin cancer & fibrosis | Dystrophic | DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
3MEuro Call 2012 | Prof. Leena Bruckner- Tuderman | University Freiburg Medical Center, Departement of Determatology, GERMANY | 2 years |
| DEBRA Austria | |
3MEuro Call 2012 | Prof. Ellen Brigitte Lane | IMB - Institute of Medical Biology, SINGAPORE | 2 years |
|
| DEBRA Austria |
3MEuro Call 2012 | Prof. Peter Marinkovich | Stanford University, California, USA | 3 years |
|
|
DEBRA Austria |
3MEuro Call 2012 | Dr. Waseem Qasim | Molecular Immunology Unit UCL Institute of Child Health, London, UK | 3 years | DEBRA Austria | ||
3MEuro Call 2012 | Prof. Dennis Roop | University of Colorade, Denver, USA | 3 years | DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2011 | Prof. Leena Bruckner- Tuderman | University Freiburg Medical Center, Departement of Dermatology, GERMANY | 3 years+1 | Symptom prevention & relief | Dystrophic | DEBRA Austria |
All Priorities Call 2011 | Prof. Johann Bauer | PMU, Salzburg, AUSTRIA | 3 years | Molecular therapy, cellular therapy |
| DEBRA Austria |
All Priorities Call 2011 | Prof. Mitchell Cairo | New York Medical College, New York, USA | 2 years +1 | Molecular therapy, cellular therapy | Dystrophic |
DEBRA Austria |
All Priorities Call 2011 | Prof. Ellen Brigitte Lane | IMB - Institute of Medical Biology, SINGAPORE | 3 years | Molecular therapy | Simplex | DEBRA Austria |
All Priorities Call 2011 | Dr. Derry Charles Roopenian | The Jackson Laboratory, Bar Harbor, Main, USA | 1 year | EB genetics, epigenetics & biology | Junctional | DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2010 | Dr. Cedric Gaggioli | A.D.S.M. Association pour le Développment des Sciences Médicales, Faculté de Médicine, Nice, FRANCE | 1 year | DEBRA Austria | ||
All Priorities Call 2010 | Prof. John McGrath | King's College London, School of Medicine, St. John's Institute of Dermatology, UK | 2 years + 9 months | Symptom prevention & relief | Dystrophic | DEBRA Austria |
All Priorities Call 2010 | Dr. Alessandra Recchia | Centre fro regenerative Medicine, University of Modena and Reggio Emilia, ITALY | 2 years | Molecular therapy, cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2010 | Prof. Dennis Roop | University of Colorado, Denver, USA | 2 years |
DEBRA Austria | ||
All Priorities Call 2010 | Prof. John Sundberg | The Jackson Laboratory, Bar Harbor, USA | 4 months | DEBRA Austria | ||
All Priorities Call 2010 | Dr. Jakub Tolar | University of Minnesota, Departement of Pediatric Hermatology - Oncology / Blood and bone Marrow Transplantation, USA | 2 years | DEBRA Austria |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2009 | Prof. Mitchell Cairo | Columbia University, Departement of Medicine and Pathology, New York, USA | 1 year | DEBRA Austria | ||
All Priorities Call 2009 | Dr. Laurent Gagnoux-Palacios | A.D.S.M. Association pour le Développement des Sciences Médiacles, Faculté de Médicine, Nice, FRANCE | 3 years |
| DEBRA Austria | |
All Priorities Call 2009 | Prof. Josef Penninger | IMBA Institute of Molecular Biotechnology, Vienna, Austria | 2 years + 6 months | Cellular therapy | Dystrophic | DEBRA Austria |
All Priorities Call 2009 | Prof. Colin Johada | Durham University, School of Biological and Biomedical Sciences, Durham, UK | 2 years |
DEBRA Austria | ||
All Priorities Call 2009 | Dr. John F. Marshall | Queen Mary University of London, Barts and London Medical School, Institute of Cancer, Centre for Tumour Biology, London, UK | 2 years | DEBRA Austria | ||
All Priorities Call 2009 | Dr. Andrew South | Ninewells Hospital and Medical School, Centre for Oncology and Molecular Medicine, Dundee, UK | 1 year | DEBRA Austria | ||
All Priorities Call 2009 | Dr. Wensin Wang | NUIG National University of Ireland, Galway, Department of Mechanical and Biomedical Engineering, Galway, IRELAND | 1,5 years |
| Grant Round/Call | Project lead | Organisation/Institute | Duration | Research area | EB-type | Funder(s) |
All Priorities Call 2007 | Prof. Peter Marinkovich | Stanford University, California, USA | 1 year | DEBRA Austria | ||
All Priorities Call 2007 | Dr. Olga Igoucheva | Jefferson Medical College, Departement of Dermatology and Cutaneous Biology, hiladelphia, USA | 2 years | DEBRA Austria |
